# Editorial: Emerging trends in cardiac and skeletal muscle pharmacotherapy

**Authors:** Young Hoon Son, Ivan Vechetti, Dawn Katrina Coletta

PMC · DOI: 10.3389/fphar.2025.1619972 · Frontiers in Pharmacology · 2025-05-15

## Full-text entities

- **Genes:** VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}
- **Diseases:** cardiotoxicity (MESH:D066126), muscle atrophy (MESH:D009133), sepsis (MESH:D018805), myocardial injury (MESH:D009202), cardiovascular and metabolic disorders (MESH:D024821), muscle-related diseases (MESH:D009135), peripheral artery disease (MESH:D058729), cancer cachexia (MESH:D009369), ischemic (MESH:D002545)
- **Chemicals:** doxorubicin (MESH:D004317), glucose (MESH:D005947), linarin (MESH:C008282), lipid (MESH:D008055), simvastatin (MESH:D019821), celecoxib (MESH:D000068579), LDL-C (-), metformin (MESH:D008687), TMZ (MESH:D014292)
- **Species:** Homo sapiens (human, species) [taxon 9606], Chrysanthemum indicum (species) [taxon 146995]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12119251/full.md

---
Source: https://tomesphere.com/paper/PMC12119251